

# Marina Montagnani Marelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4186231/publications.pdf>

Version: 2024-02-01

57  
papers

2,087  
citations

218677

26  
h-index

233421

45  
g-index

58  
all docs

58  
docs citations

58  
times ranked

2545  
citing authors

#	ARTICLE	IF	CITATIONS
1	GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. <i>Human Reproduction Update</i> , 2016, 22, 358-381.	10.8	156
2	GnRH Receptors in Cancer: From Cell Biology to Novel Targeted Therapeutic Strategies. <i>Endocrine Reviews</i> , 2012, 33, 784-811.	20.1	137
3	The Luteinizing Hormone-Releasing Hormone Receptor in Human Prostate Cancer Cells: Messenger Ribonucleic Acid Expression, Molecular Size, and Signal Transduction Pathway <sup>1</sup> . <i>Endocrinology</i> , 1999, 140, 5250-5256.	2.8	123
4	The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. <i>Frontiers in Neuroendocrinology</i> , 2003, 24, 279-295.	5.2	114
5	Role of Endoplasmic Reticulum Stress in the Anticancer Activity of Natural Compounds. <i>International Journal of Molecular Sciences</i> , 2019, 20, 961.	4.1	93
6	LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 709-720.	4.1	90
7	Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells. <i>Cell Death and Disease</i> , 2018, 9, 889.	6.3	82
8	Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. <i>Prostate</i> , 2000, 45, 238-244.	2.3	69
9	Î-tocotrienol induces apoptosis, involving endoplasmic reticulum stress and autophagy, and paraptosis in prostate cancer cells. <i>Cell Proliferation</i> , 2019, 52, e12576.	5.3	69
10	Estrogen Receptor $\hat{2}$ in Melanoma: From Molecular Insights to Potential Clinical Utility. <i>Frontiers in Endocrinology</i> , 2016, 7, 140.	3.5	57
11	Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 3930-3937.	3.6	57
12	Vitamin E Î-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells. <i>Scientific Reports</i> , 2016, 6, 30502.	3.3	56
13	Gonadotropin-Releasing Hormone (GnRH) Receptors in Tumors: a New Rationale for the Therapeutical Application of GnRH Analogs in Cancer Patients?. <i>Current Cancer Drug Targets</i> , 2006, 6, 257-269.	1.6	54
14	Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3791-3797.	3.6	53
15	Clusterin Isoforms Differentially Affect Growth and Motility of Prostate Cells: Possible Implications in Prostate Tumorigenesis. <i>Cancer Research</i> , 2007, 67, 10325-10333.	0.9	53
16	Targeting melanoma stem cells with the Vitamin E derivative Î-tocotrienol. <i>Scientific Reports</i> , 2018, 8, 587.	3.3	46
17	Activation of the orphan nuclear receptor ROR $\hat{1}$ counteracts the proliferative effect of fatty acids on prostate cancer cells: Crucial role of 5-lipoxygenase. <i>International Journal of Cancer</i> , 2004, 112, 87-93.	5.1	45
18	Anticancer properties of tocotrienols: A review of cellular mechanisms and molecular targets. <i>Journal of Cellular Physiology</i> , 2019, 234, 1147-1164.	4.1	45

#	ARTICLE	IF	CITATIONS
19	Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. <i>International Journal of Cancer</i> , 1998, 76, 506-511.	5.1	42
20	GnRH in the Human Female Reproductive Axis. <i>Vitamins and Hormones</i> , 2018, 107, 27-66.	1.7	39
21	Cellular and molecular biology of cancer stem cells in melanoma: Possible therapeutic implications. <i>Seminars in Cancer Biology</i> , 2019, 59, 221-235.	9.6	39
22	Estrogen Receptor $\hat{I}^2$ Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. <i>PLoS ONE</i> , 2015, 10, e0134396.	2.5	38
23	Type I Gonadotropin-Releasing Hormone Receptor Mediates the Antiproliferative Effects of GnRH-II on Prostate Cancer Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1761-1767.	3.6	36
24	Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression.. <i>Endocrine-Related Cancer</i> , 2003, 10, 161-167.	3.1	35
25	The Luteinizing Hormone-Releasing Hormone Receptor in Human Prostate Cancer Cells: Messenger Ribonucleic Acid Expression, Molecular Size, and Signal Transduction Pathway. <i>Endocrinology</i> , 1999, 140, 5250-5256.	2.8	30
26	Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1996, 56, 107-111.	2.5	28
27	The Role of HSPB8, a Component of the Chaperone-Assisted Selective Autophagy Machinery, in Cancer. <i>Cells</i> , 2021, 10, 335.	4.1	28
28	Activation of the orphan nuclear receptor ROR $\gamma$ induces growth arrest in androgen-independent DU 145 prostate cancer cells. <i>Prostate</i> , 2001, 46, 327-335.	2.3	25
29	Semi-preparative HPLC purification of $\hat{I}$ -tocotrienol ( $\hat{I}$ -T3) from <i>Elaeis guineensis</i> Jacq. and <i>Bixa orellana</i> L. and evaluation of its <i>in vitro</i> anticancer activity in human A375 melanoma cells. <i>Natural Product Research</i> , 2018, 32, 1130-1135.	1.8	24
30	Unraveling the molecular mechanisms and the potential chemopreventive/therapeutic properties of natural compounds in melanoma. <i>Seminars in Cancer Biology</i> , 2019, 59, 266-282.	9.6	23
31	Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9511.	4.1	23
32	Growth of the androgen-dependent tumor of the prostate: Role of androgens and of locally expressed growth modulatory factors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995, 53, 401-405.	2.5	20
33	Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells. <i>International Journal of Cancer</i> , 2001, 92, 733-737.	5.1	20
34	Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the $\alpha$ v $\beta$ 3 integrin and PI3-K/Akt signaling. <i>International Journal of Oncology</i> , 2006, 28, 723-30.	3.3	20
35	Tocotrienols and Cancer: From the State of the Art to Promising Novel Patents. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019, 14, 5-18.	1.6	19
36	Novel insights into GnRH receptor activity: Role in the control of human glioblastoma cell proliferation. <i>Oncology Reports</i> , 2009, 21, 1277-82.	2.6	18

#	ARTICLE	IF	CITATIONS
37	Evaluation of a Stable Gonadotropin-Releasing Hormone Analog in Mice for the Treatment of Endocrine Disorders and Prostate Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 336, 613-623.	2.5	17
38	Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor. <i>International Journal of Oncology</i> , 2015, 46, 243-253.	3.3	16
39	Luteinizing Hormone-Releasing Hormone Agonists Interfere with the Mitogenic Activity of the Insulin-Like Growth Factor System in Androgen-Independent Prostate Cancer Cells. <i>Endocrinology</i> , 1999, 140, 329-334.	2.8	16
40	Androgen-dependent prostatic tumors: biosynthesis and possible actions of LHRH. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1994, 49, 347-350.	2.5	15
41	Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce Melanoma Angiogenesis. <i>Endocrinology</i> , 2010, 151, 4643-4653.	2.8	15
42	Gonadotropin-Releasing Hormone Agonists Sensitize, and Resensitize, Prostate Cancer Cells to Docetaxel in a p53-Dependent Manner. <i>PLoS ONE</i> , 2014, 9, e93713.	2.5	14
43	Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3791-3797.	3.6	14
44	Apoptosis-mediated anticancer activity in prostate cancer cells of a chestnut honey ( <i>Castanea sativa</i> ) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.7	12
45	Targeting Hormonal Signaling Pathways in Castration Resistant Prostate Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2014, 9, 267-285.	1.6	10
46	Characterization of a soluble LHRH-degrading activity in the rat ventral prostate. <i>Prostate</i> , 1993, 23, 315-328.	2.3	9
47	Molecular mechanisms of the antimetastatic activity of nuclear clusterin in prostate cancer cells. <i>International Journal of Oncology</i> , 2011, 39, 225-34.	3.3	8
48	Gonadotropin-releasing hormone agonists suppress melanoma cell motility and invasiveness through the inhibition of $\alpha 3$ integrin and MMP-2 expression and activity. <i>International Journal of Oncology</i> , 1992, 33, 405.	3.3	7
49	Growth factors in steroid-responsive prostatic tumor cells. <i>Steroids</i> , 1996, 61, 222-225.	1.8	7
50	<i>In Vitro</i> Chronic Administration of ERbeta Selective Ligands and Prostate Cancer Cell Growth: Hypotheses on the Selective Role of 3beta-Adiol in AR-Positive RV1 Cells. <i>BioMed Research International</i> , 2014, 2014, 1-14.	1.9	7
51	Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. <i>International Journal of Oncology</i> , 2007, 30, 261.	3.3	6
52	Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. <i>International Journal of Oncology</i> , 2007, 30, 261-71.	3.3	4
53	HUMAN PROSTATIC-CARCINOMA CELL-LINE LNCAP DEGRADES LUTEINIZING-HORMONE-RELEASING HORMONE. <i>International Journal of Oncology</i> , 1995, 6, 1231-6.	3.3	2
54	LHRH as a growth-inhibitory factor in prostatic tumor cells: possible mechanism of action. <i>Endocrine-Related Cancer</i> , 1996, 3, 211-216.	3.1	2

#	ARTICLE	IF	CITATIONS
55	LH-RH and Somatostatin: Examples of Peptidergic Control of Prostate Cancer Growth. Contributions To Oncology / Beitrage Zur Onkologie, 1995, 50, 332-344.	0.1	0
56	FROM EMERGING BIOLOGICAL INSIGHTS TO NOVEL TREATMENT STRATEGIES IN PROSTATE CANCER. Istituto Lombardo - Accademia Di Scienze E Lettere - Rendiconti Di Scienze, 2014, , .	0.0	0
57	REPRODUCTIVE FUNCTION AND ANTITUMOR ACTIVITY: DIFFERENT ROLES FOR THE HYPOTHALAMIC HORMONE GnRH. Istituto Lombardo - Accademia Di Scienze E Lettere - Incontri Di Studio, 0, , .	0.0	0